Genprex, Inc. filed a Form 8-K on October 28, 2026, announcing that research from its sponsored collaboration with Meharry Medical College will be presented at the Gerontological Society of America 2026 Annual Scientific Meeting in National Harbor, Maryland.

Key Highlights

  • GSA 2026 presentation: Research titled "TUSC2 Gene Therapy in Humans Induces a Cellular-Resilience Program" will be presented as a Late Breaking Poster during a session on November 4, 2026, from 6:00 to 7:15 p.m. ET at the Gaylord National Resort and Convention Center, Exhibit Hall C-D.
  • Presenter: Mark S. Berger, MD, Chief Medical Officer of Genprex, will present the poster (Abstract ID: 2489375).
  • Research focus: The work investigates the role of TUSC2, the tumor suppressor gene used in Genprex's lead oncology candidate REQORSA (quaratusugene ozeplasmid), in mitochondrial biology, cellular resilience, and molecular processes associated with aging.
  • Collaboration origin: Genprex established the sponsored research collaboration with Meharry Medical College in Nashville, Tennessee, in 2024.
  • Potential scope: According to the filing, the company believes the work represents an opportunity to explore applications beyond oncology, alongside its established development priorities in lung cancer and diabetes.

Genprex and Meharry Medical College Present TUSC2 Aging Research at GSA 2026

According to the Form 8-K filed with the Securities and Exchange Commission by Genprex, Inc. (NASDAQ:GNPX) on October 28, 2026, the company issued a press release announcing that research conducted under its sponsored collaboration with Meharry Medical College will be featured at the Gerontological Society of America 2026 Annual Scientific Meeting, scheduled for November 4-7, 2026, in National Harbor, Maryland. The filing states the collaboration was established in 2024 to investigate aspects of REQORSA biology, including mitochondrial metabolism and molecular aging and their potential relationship to cancer.

The filing explains that REQORSA is designed to restore tumor-suppressor function through delivery of the TUSC2 gene. Research conducted through the collaboration, according to the filing, is examining the broader biological activities of REQORSA, including its involvement in cellular metabolism and stress-response pathways. The filing further notes that Genprex is working with Meharry Medical College to expand the scope of this research, with additional work intended to investigate the role of REQORSA in aging-related biological processes.

The filing states that additional research will be needed to determine whether these findings could support future therapeutic development. The company's statements regarding potential future applications beyond oncology are characterized in the filing as forward-looking statements subject to risks and uncertainties, and the filing directs readers to risk factors in Genprex's Annual Report on Form 10-K for the year ended December 31, 2025. The filing was signed by Ryan M. Confer, President, Chief Executive Officer and Chief Financial Officer.

What Was Disclosed

Genprex disclosed via an 8-K that research from its Meharry Medical College collaboration will be presented at the GSA 2026 Annual Scientific Meeting on November 4, 2026, focusing on TUSC2's role in cellular resilience and aging-related biology, with Mark S. Berger, MD, as presenter.